Drug · CHEMBL645
BISOPROLOL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. BISOPROLOL. Drugs and targets, record CHEMBL645. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL645
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ADRB1 | Beta-1 adrenergic receptor | Beta-1 adrenergic receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/153 |
Source ChEMBL
Diseases36
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| hypertensive disorder | Approval | PMDA and TTD | 17 | 15 | https://conductscience.org/library/drugs?q=MONDO_0005044 |
| heart failure | Phase 3 | ClinicalTrials.gov | 9 | 9 | https://conductscience.org/library/drugs?q=MONDO_0005252 |
| atrial fibrillation | Phase 3 | ClinicalTrials.gov | 8 | 8 | https://conductscience.org/library/drugs?q=MONDO_0004981 |
| coronary artery disorder | Unknown | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0005010 |
| myocardial infarction | Phase 3 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0005068 |
| chronic obstructive pulmonary disease | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005002 |
| congestive heart failure | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005009 |
| angina unstable | Phase 2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=EFO_0020925 |
| chronic rhinosinusitis | Phase 2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0006031 |
| dilated cardiomyopathy | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0005021 |
1 to 10 of 36Source Open Targets
See all 36 diseasesTrials90
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 36 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00391846 | Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone | Phase 4 | 252 | 2012-06-18 | bisoprolol | Its name | ClinicalTrials.gov |
| NCT01079962 | An Active-controlled, Clinical Trial to Assess Central Hemodynamic Effects of Bisoprolol in Hypertensive Patients (Central Hemodynamic Assessment Measured in Patient With HypertensION [CHAMPION]) | Phase 4 | 209 | 2012-10-02 | bisoprolol | Its name | ClinicalTrials.gov |
| NCT01066039 | Phase 4 Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Subjects With Suboptimal Blood Pressure Control | Phase 4 | 202 | 2014-07-04 | bisoprolol | Its name | ClinicalTrials.gov |
| NCT01977794 | Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension | Phase 3 | 200 | 2016-08-11 | bisoprolol | Its name | ClinicalTrials.gov |
| NCT01508325 | Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients | Phase 4 | 186 | 2015-05-13 | bisoprolol | Its name | ClinicalTrials.gov |
| NCT01074307 | A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea | Phase 4 | 180 | 2014-02-14 | bisoprolol | Its name | ClinicalTrials.gov |
| NCT01251146 | A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension | Phase 4 | 177 | 2012-11-30 | bisoprolol | Its name | ClinicalTrials.gov |
| NCT02391337 | Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) | Phase 4 | 161 | 2021-06-16 | bisoprolol | Its name | ClinicalTrials.gov |
| NCT01190436 | A 12-week, Multicentric Study to Evaluate the Safety and Efficacy of Bisoprolol in Filipino Hypertensive Subjects With Diabetes | Phase 4 | 125 | 2014-05-23 | bisoprolol | Its name | ClinicalTrials.gov |
| NCT02355821 | Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women | 114 | 2021-09-01 | bisoprolol | Its name | ClinicalTrials.gov |
1 to 10 of 90
See all 90 trialsComparisons in its trials34
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Propranolol or Carvedilol vs Atenolol, Bisoprolol or Sotalol: deaths from any cause | 0 of 222,015 | 0 of 222,015 | 444,030 | NCT05794997 | Trial comparisons |
| Guided by NT-proBNP vs Not Guided by NT-proBNP: Discontinuations | 8 of 127 | 6 of 125 | 252 | NCT00391846 | Trial comparisons |
| Guided by NT-proBNP vs Not Guided by NT-proBNP: serious adverse events | 46 of 127 | 41 of 125 | 252 | NCT00391846 | Trial comparisons |
| Guided by NT-proBNP vs Not Guided by NT-proBNP: Number of CV Deaths | 4 of 123 | 5 of 123 | 246 | NCT00391846 | Trial comparisons |
| Bisoprolol vs Atenolol: Number of Participants With Adverse Events (AEs) | 36 of 105 | 32 of 104 | 209 | NCT01079962 | Trial comparisons |
| Bisoprolol vs Atenolol: serious adverse events | 7 of 105 | 3 of 104 | 209 | NCT01079962 | Trial comparisons |
| Amlodipine Failed Group vs Bisoprolol Failed Group: serious adverse events | 1 of 100 | 2 of 100 | 200 | NCT01977794 | Trial comparisons |
| Bisoprolol vs Metoprolol: serious adverse events | 2 of 93 | 0 of 93 | 186 | NCT01508325 | Trial comparisons |
| Low Dose Bisoprolol vs High Dose Bisoprolol: Number of Participants With Adverse Events (AEs) | 45 of 66 | 73 of 114 | 180 | NCT01074307 | Trial comparisons |
| Low Dose Bisoprolol vs High Dose Bisoprolol: serious adverse events | 16 of 66 | 9 of 114 | 180 | NCT01074307 | Trial comparisons |
1 to 10 of 34
See all 34 comparisons in its trialsPapers from its trials89
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL645
GET https://conductscience.org/api/drugs/v1/CHEMBL645/diseases?page=2